Antibody responses to the penicilloyl moiety were recorded in patients treated intramuscularly with ámpicillin for respiratory infections. For practical reasons this was performed at two clinics. At each clinic, two commercially available ampicillin preparations were used in a single-blind, randomised study. One of the preparations at each clinic was of high-grade purity and the other was slightly contaminated, according to a radioimmunoassay. There was the same heterogeneity in the patient material between the two clinics. The results showed a slight but significant (p < 0.001) increase in IgM penicilloyl antibodies in the group of patients treated with the pure penicillin but not in those treated with the contaminated penicillin. When the patients in the two studies were analysed jointly, the increase in IgM antibodies was significantly greater (p < 0.05) in the group treated with pure penicillin than in that treated with impure penicillin. The difference in antibody formation between the patient groups treated with pure or contamined ampicillin at each clinic was not significant, however. An immunological activity of the impurities suppressing; the IgM antibody response is suggested.

This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.